Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).

被引：1
|
作者：
Sznol, Mario
Kluger, Harriet M.
Callahan, Margaret K.
Postow, Michael Andrew
Gordon, Ruth Ann
Segal, Neil Howard
Rizvi, Naiyer A.
Lesokhin, Alexander M.
Atkins, Michael B.
Kirkwood, John M.
Burke, Matthew M.
Ralabate, Amanda L.
Rivera, Angel L.
Kronenberg, Stephanie Anne
Agunwamba, Blessing
Feely, William
Hong, Quan
Krishnan, Suba
Gupta, Ashok Kumar
Wolchok, Jedd D.
机构：
[1] Yale Canc Ctr, New Haven, CT USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[4] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[5] Bristol Myers Squibb, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA9003
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
    Grosso, Joseph
    Horak, Christine E.
    Inzunza, David
    Cardona, Diana M.
    Simon, Jason S.
    Gupta, Ashok Kumar
    Sankar, Vindira
    Park, Jong-Soon
    Kollia, Georgia
    Taube, Janis M.
    Anders, Robert
    Jure-Kunkel, Maria
    Novotny, Jim, Jr.
    Taylor, Clive R.
    Zhang, Xiaoling
    Phillips, Therese
    Simmons, Pauline
    Cogswell, John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC).
    Amin, Asirn
    Ernstoff, Marc S.
    Infante, Jeffrey R.
    Heng, Daniel Yick Chin
    Rini, Brian I.
    Plimack, Elizabeth R.
    McDermott, David F.
    Kollmannsberger, Christian K.
    Reaume, Martin Neil
    Spratlin, Jennifer L.
    Knox, Jennifer J.
    Voss, Martin Henner
    Pal, Sumanta Kumar
    Shen, Yuri
    Dhar, Arindarn
    Hammers, Hans J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
    Ramalingam, S. S.
    Mazieres, J.
    Planchard, D.
    Stinchcombe, T. E.
    Dy, G. K.
    Antonia, S. J.
    Horn, L.
    Lena, H.
    Minenza, E.
    Mennecier, B.
    Otterson, G. A.
    Campos, L. T.
    Gandara, D. R.
    Levy, B. P.
    Nair, S. G.
    Zalcman, G.
    Wolf, J.
    Baudelet, C.
    Lestini, B. J.
    Rizvi, N. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 (05): : 1266 - 1267
  • [34] CLINICAL ACTIVITY AND SAFETY OF ANTI-PROGRAMMED DEATH-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) IN PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL)
    Sosman, J.
    Sznol, M.
    McDermott, D. F.
    Carvajal, R.
    Lawrence, D. P.
    Topalian, S. L.
    Wigginton, J. M.
    Kollia, G.
    Gupta, A.
    Hodi, F. S.
    ANNALS OF ONCOLOGY, 2012, 23 : 361 - 361
  • [35] A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).
    Robert, Caroline
    Ascierto, Paolo Antonio
    Maio, Michele
    Hernberg, Micaela
    Schmidt, Henrik
    Waxman, Ian
    Garbe, Claus
    Lebbe, Celeste
    Hauschild, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] CLINICAL ACTIVITY, SAFETY AND SUBPOPULATION RESPONSE ANALYSIS OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS (PT) WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Brahmer, J. R.
    Horn, L.
    Antonia, S. J.
    Spigel, D. R.
    Sequist, L. V.
    Ahlers, C. M.
    Sankar, V.
    Kollia, G.
    Gettinger, S.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S39 - S39
  • [37] Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Gettinger, S. N.
    Horn, L.
    Gandhi, L.
    Spigel, D. R.
    Antonia, S. J.
    Rizvi, N. A.
    Powderly, J. D.
    Heist, R. S.
    Carvajal, R. D.
    Jackman, D. M.
    Sequist, L. V.
    Smith, D. C.
    Leming, P. D.
    Topalian, S. L.
    Hodi, F.
    Sznol, M.
    Harbison, C. T.
    Kollia, G. D.
    Brahmer, J. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S34 - S34
  • [38] PHASE I STUDY OF ONO-4538 (BMS-936558), AN ANTI PD-1 ANTIBODY, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Yamamoto, N.
    Yamada, Y.
    Nokihara, H.
    Asahina, H.
    Shibata, T.
    Tamura, Y.
    Seki, Y.
    Honda, K.
    Tanabe, Y.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 159 - 159
  • [39] Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis
    Sangro, Bruno
    Crocenzi, Todd S.
    Welling, Theodore Hobart
    Inarrairaegui, Mercedes
    Prieto, Jesus
    Fuertes, Carmen
    Delanty, Laurie
    Feely, William
    Anderson, Jeffrey
    Grasela, Dennis M.
    Wigginton, Jon M.
    Gupta, Ashok Kumar
    Melero, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] Phase II Study of Nivolumab (ONO-4538/BMS-936558) for Esophageal Cancer: Clinical activity by PD-L1 expression analysis
    Hara, Hiroki
    Kojima, Takashi
    Hironaka, Shuichi
    Kato, Ken
    Tsushima, Takahiro
    Ura, Takashi
    Doki, Yuichiro
    Ohtsu, Atsushi
    Hamamoto, Yasuo
    Kitagawa, Yuko
    ANNALS OF ONCOLOGY, 2016, 27
12345